Tirzepatide Microdosing Chart

Medical Disclaimer

This website is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or stopping any medication or supplement. Dosage information reflects published FDA-approved labeling or publicly available clinical trial data — individual treatment decisions must be made by a licensed physician.

About tirzepatide

Microdosing tirzepatide refers to using doses below the standard FDA-approved titration schedule. Some providers and patients explore sub-therapeutic dosing to minimize side effects or for maintenance after significant weight loss. This is not an FDA-approved protocol — always work with your prescribing provider.

Indication

Experimental/off-label sub-therapeutic dosing. This page is for informational reference only. Always follow your provider's guidance.

Standard Titration Schedule

Frequency: Once weekly or as prescribed by your provider. Maximum approved dose: Varies (sub-therapeutic, below 2.5 mg standard start).

Week / Phase	Dose	At 2.5 mg/mL	At 5 mg/mL	Notes
Starting point	0.5 mg	2 units (2.5 mg/mL)	1 units (5 mg/mL)	Common starting microdose. Not FDA-approved. Compounded tirzepatide required.
Optional step-up	1 mg	4 units (2.5 mg/mL)	2 units (5 mg/mL)	Step-up microdose. Still below FDA start of 2.5 mg.
Mid-range microdose	1.5 mg	6 units (2.5 mg/mL)	3 units (5 mg/mL)	Mid-range between 1 mg and standard 2.5 mg start.
Near-standard	2 mg	8 units (2.5 mg/mL)	4 units (5 mg/mL)	Just below the standard 2.5 mg start. Transition point to standard protocol.

Units shown assume a standard U-100 insulin syringe (100 units = 1 mL). Always confirm your vial concentration with your pharmacy.

Dose Calculator

Enter your prescribed dose and vial concentration to calculate how many units to draw.

mg ↔ Units Dose Calculator

Convert between milligrams and insulin-syringe units for compounded GLP-1 medications. Uses a standard U-100 syringe (100 units = 1 mL).

Medication

Vial Concentration (mg/mL)

Dose (mg)

Units (U-100 syringe)100 units

Volume1.000 mL

2.5 mg at 2.5 mg/mL → 1.000 mL → 100 units on a U-100 (100-unit / 1 mL) insulin syringe

Always verify calculations with your prescribing provider or pharmacist before administering any medication. This calculator is for reference only.

Injection Sites

Abdomen

Same subcutaneous injection technique as standard dosing.

Rotate sites to prevent lipodystrophy
Proper technique matters more at micro-doses

Thigh

Outer thigh subcutaneous tissue.

Ensure you're injecting subcutaneously, not intramuscularly

Storage Instructions

Store compounded vials as directed by your pharmacy (typically refrigerated)
Check expiration dates on compounded preparations carefully
Reconstituted peptides may have shorter shelf life — confirm with your pharmacy

Common Side Effects

Contact your healthcare provider if side effects are severe or persistent.

Reduced nausea compared to standard dosing
Possible reduced efficacy
Injection site reactions
Individual responses vary significantly

Frequently Asked Questions

What is microdosing tirzepatide?

Microdosing tirzepatide means using doses smaller than the FDA-approved 2.5 mg starting dose. Some providers prescribe this approach for patients who are very sensitive to GI side effects, or for maintaining results after reaching goal weight. It requires compounded tirzepatide.

Is microdosing tirzepatide effective for weight loss?

Clinical evidence at sub-therapeutic doses is limited. The FDA-approved efficacy data is based on the standard titration schedule. Some patients report appetite suppression at lower doses, but there are no robust clinical trials specifically on tirzepatide microdosing for weight loss.

Can I microdose tirzepatide with the auto-injection pen?

No. The brand-name auto-injection pens (Mounjaro, Zepbound) deliver fixed doses. Microdosing requires compounded tirzepatide in a vial with a separate insulin syringe for precise measurement.